The board of directors of Sirnaomics Ltd. announced that the Board has received a letter of resignation from Dr. Michael V. Molyneaux (Dr. Molyneaux) to resign as an executive Director effective from November 30, 2023, as Dr. Molyneaux wishes to devote more time to his other commitments. Dr. Molyneaux has confirmed that he had no disagreement with the Board and there were no other matters relating to his resignation that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited. Dr. Molyneaux has also resigned as the Chief Medical Officer of the Group effective from November 30, 2023.

The Board announced that Dr. Francois Lebel (Dr. Lebel) has been appointed as the Chief Medical Officer of the Group, re-designated from the position of Senior Vice President for preclinical and clinical development effective from December 1, 2023. Dr. Lebel is the Chief Medical Officer of the Group and takes a leading role in the Group's late-stage product development of the innovative RNAi drug candidates. He joined the Group in July 2023 as the Senior Vice President for preclinical and clinical development of the Group.

Dr. Lebel is a strategic leader with broad drug development experience including immuno-oncology and nucleic acid therapeutics. Throughout his 30-year solid biopharma industry career with Baxter Healthcare, Medlmmune, Chiron Corporation and others, Dr. Lebel has designed and managed international research programs and development organizations to successfully achieve multiple product marketing approvals. Prior to joining the Group, Dr. Lebel most recently served as the executive vice president for research and development and chief medical officer of Spectrum Pharmaceuticals from November 2018 to January 2023, where he was responsible for preclinical and clinical development, regulatory affairs and pharmacovigilance/drug safety.

His commitment to quality and speed of execution resulted in another novel drug product marketing authorization at the U.S. Food and Drug Administration (FDA) in 2022. Dr. Lebel received his bachelor's degree in molecular biology and a medical degree from the University of Ottawa, Canada, and completed his post graduate training at McGill University and Harvard Medical School. He is Board Certified in Internal Medicine and is a fellow of the Royal College of Physicians of Canada.